JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Ligand Pharmaceuticals Inc

Cerrado

SectorSanidad

230.04 0.73

Resumen

Variación precio

24h

Actual

Mínimo

227.17

Máximo

231.09

Métricas clave

By Trading Economics

Ingresos

-72M

45M

Ventas

-56M

60M

P/B

Media del Sector

37.811

60.328

Margen de beneficios

75.058

Empleados

47

EBITDA

-83M

66M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+9.15% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1B

4.6B

Apertura anterior

229.31

Cierre anterior

230.04

Noticias sobre sentimiento de mercado

By Acuity

29%

71%

74 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2026, 19:19 UTC

Adquisiciones, fusiones, absorciones

Intertek Group Rejects EQT's Revised Offer

24 abr 2026, 23:37 UTC

Adquisiciones, fusiones, absorciones

Scoring the Cook Era -- Barrons.com

24 abr 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

24 abr 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 20:09 UTC

Ganancias

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 abr 2026, 19:48 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 19:25 UTC

Adquisiciones, fusiones, absorciones

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 abr 2026, 19:22 UTC

Ganancias

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 abr 2026, 19:06 UTC

Ganancias

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 abr 2026, 19:05 UTC

Charlas de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 abr 2026, 18:30 UTC

Adquisiciones, fusiones, absorciones

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 abr 2026, 18:28 UTC

Adquisiciones, fusiones, absorciones

Intertek Rejects Revised EQT Offer

24 abr 2026, 18:12 UTC

Charlas de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 abr 2026, 18:06 UTC

Charlas de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 abr 2026, 17:42 UTC

Ganancias

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 abr 2026, 17:28 UTC

Ganancias

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 abr 2026, 17:28 UTC

Charlas de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 abr 2026, 17:12 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

24 abr 2026, 17:11 UTC

Charlas de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 abr 2026, 17:09 UTC

Charlas de Mercado
Ganancias

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 abr 2026, 17:09 UTC

Adquisiciones, fusiones, absorciones

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 abr 2026, 17:06 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 abr 2026, 16:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Financial Services Roundup: Market Talk

24 abr 2026, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

24 abr 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Ligand Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

9.15% repunte

Estimación a 12 Meses

Media 252.43 USD  9.15%

Máximo 282 USD

Mínimo 230 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ligand Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

102.5 / 109.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

74 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.